PCPierre G. Coulie

Pierre G. Coulie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pierre G. Coulie has a total of 48 co-authors. Here are the top co-authors by number of shared publications:

  • Thierry Boon

    Christian de Duve Institute of Cellular Pathology, Université Catholique de Louvain, Brussels, Belgium

    6 shared publications
  • Takeshi Hanagiri

    The Second Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan

    3 shared publications
  • Christophe Lurquin

    Cellular Genetics Unit, Université de Louvain, B-1200 Brussels, Belgium

    2 shared publications
  • Didier Colau

    Christian de Duve Institute of Cellular Pathology, Université Catholique de Louvain, Brussels, Belgium

    2 shared publications
  • Francis Brasseur

    Christian de Duve Institute of Cellular Pathology, Université Catholique de Louvain, Brussels, Belgium

    2 shared publications
  • Kosei Yasumoto

    The Second Department of Surgery, University of Occupational and Environmental Health, Kitakyushu, Japan

    2 shared publications

Latest Publications

  • Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195–203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules

    by Tomoko So, Takeshi Hanagiri, Jacques Chapiro, Didier Colau, Francis Brasseur, Kosei Yasumoto, Thierry Boon, Pierre G. Coulie

    Gene MAGE-A3 encodes tumor-specific antigenic peptides recognized by T cells on many tumors. MAGE-A3 peptides presented by HLA class I molecules have been identified using CD8 lymphocytes stimulated with cells that either expressed gene MAGE-A3 or were pulsed with candidate peptides. One antigen identified with the latter method is peptide MAGE-A3195–203 IMPKAGLLI, presented by HLA-A24 molecules. It has been used to vaccinate advanced cancer patients. Here, we have used HLA/peptide tetramers to detect T cells recognizing this peptide. Their frequency was estimated to be 2 × 10−8 of the blood CD8 cells in non-cancerous HLA-A24+ individuals, which is tenfold lower than the reported frequencies of T cells against other MAGE peptides. In the blood of a patient vaccinated with MAGE-A3, the estimated frequency was 5 × 10−7. Anti-MAGE-3.A24 cytolytic T cell clones were derived, that lysed peptide-pulsed cells with half-maximal effect at the low concentration of 500 pM. However, these CTL did not recognize a panel of HLA-A24+ tumor cells that expressed MAGE-A3 at levels similar to those found in HLA-A1+ tumor cells recognized by anti-MAGE-3.A1 CTLs. Furthermore, 293-EBNA cells transfected with MAGE-A3 and HLA-A24 constructs were hardly recognized by the anti-MAGE-3.A24 CTL clones. These results suggest that peptide MAGE-A3195–203 is poorly processed and is not an appropriate target for cancer immunotherapy.


  • Open Access

    A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma

    by Mitsuhiro Takenoyama, Jean‐Françis Baurain, Manabu Yasuda, Tomoko So, Masakazu Sugaya, Takeshi Hanagiri, Kenji Sugio, Kosei Yasumoto, Thierry Boon, Pierre G. Coulie

    We have identified an antigen recognized by cytolytic T lymphocytes (CTL) on the autologous tumor cells of a nonsmall cell lung cancer patient. The antigenic peptide, presented by HLA‐B*5201 molecules, was encoded by a mutated sequence in the gene coding for the C subunit of transcription factor NF‐Y. The mutation was present in the tumor sample from which the cell line was derived, and appeared to be unique to the tumor of this patient. In a lymph node draining the tumor, precursors of CTL recognizing the autologous tumor cells were detected at a frequency of about 1/30,000 of the CD8 cells, and 85% of them recognized the mutated NF‐YC peptide, suggesting that the patient mounted a T cell response against this antigen. These results strengthened the notion that unique tumor‐specific antigens are highly represented not only in melanoma but also in other types of tumors, like nonsmall cell lung cancer.


  • Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1

    by Takeshi Hanagiri, Nicolas Van Baren, Bart Neyns, Thierry Boon, Pierre G. Coulie

    We describe an HLA-A1 melanoma patient who has mounted a spontaneous cytolytic T cell (CTL) response against an antigenic peptide encoded by gene MAGE-A3 and presented by HLA-A1. The frequency of anti-MAGE-3.A1 CTLp was 5 x 10(-7) of the blood CD8 cells, with a dominant clonotype which was present in six out of seven independent anti-MAGE-3.A1 CTL clones. After vaccination with a recombinant poxvirus coding for the MAGE-3.A1 antigen, the blood frequency of anti-MAGE-3.A1 CTLp increased tenfold. Twenty-two independent CTL clones were derived. Surprisingly, only one of them corresponded to the dominant clonotype present before vaccination. Two new clonotypes were repeated 12 and 7 times, respectively. Our interpretation of these results is that the spontaneous anti-MAGE-3.A1 CTL response pre-existing to vaccination was polyclonal, and that the vaccine restimulated only some of these clones. To estimate the incidence of spontaneous anti-MAGE-3.A1 CTL responses in melanoma patients with a tumor expressing gene MAGE-A3, we measured the blood frequency of anti-MAGE-3.A1 T cells in 45 patients, and found only two clear responses.


  • Open Access

    High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens

    by Catherine Germeau, Wenbin Ma, Francesca Schiavetti, Christophe Lurquin, Emmanuelle Henry, Nathalie Vigneron, Francis Brasseur, Bernard Lethé, Etienne De Plaen, Thierry Velu, et al.

    After vaccination of melanoma patients with MAGE antigens, we observed that even in the few patients showing tumor regression, the frequency of anti-vaccine T cells in the blood was often either undetectable or −5 of CD8 T cells. This frequency being arguably too low for these cells to be sole effectors of rejection, we reexamined the contribution of T cells recognizing other tumor antigens. The presence of such antitumor T cells in melanoma patients has been widely reported. To begin assessing their contribution to vaccine-induced rejection, we evaluated their blood frequency in five vaccinated patients. The antitumor cytotoxic T lymphocyte (CTL) precursors ranged from 10−4 to 3 × 10−3, which is 10–10,000 times higher than the anti-vaccine CTL in the same patient. High frequencies were also observed before vaccination. In a patient showing nearly complete regression after vaccination with a MAGE-3 antigen, we observed a remarkably focused antitumoral response. A majority of CTL precursors (CTLp's) recognized antigens encoded by MAGE-C2, another cancer-germline gene. Others recognized gp100 antigens. CTLp's recognizing MAGE-C2 and gp100 antigens were already present before vaccination, but new clonotypes appeared afterwards. These results suggest that a spontaneous antitumor T cell response, which has become ineffective, can be reawakened by vaccination and contribute to tumor rejection. This notion is reinforced by the frequencies of anti-vaccine and antitumor CTLs observed inside metastases, as presented by Lurquin et al. (Lurquin, C., B. Lethé, V. Corbière, I. Théate, N. van Baren, P.G. Coulie, and T. Boon. 2004. J. Exp. Med. 201:249–257).


  • T-cell responses of vaccinated cancer patients

    by Pierre G Coulie, Pierre van der Bruggen


  • WITHDRAWN: Cytolytic T cell responses of cancer patients vaccinated with a MAGE antigen

    by Pierre G. Coulie, Vaios Karanikasa, Christophe Lurquinb, Didier Colaub, Thierry Connerottea, Takeshi Hanagiria, Aline Van Pel, Sophie Lucas, Danièle Godelaine, Christophe Lonchay, et al.


  • A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by geneMAGE-3

    by Pierre G. Coulie, Vaios Karanikas, Didier Colau, Christophe Lurquin, Claire Landry, Marie Marchand, Thierry Dorval, Vincent Brichard, Thierry Boon

    Vaccination of melanoma patients with tumor-specific antigens recognized by cytolytic T lymphocytes (CTL) produces significant tumor regressions in a minority of patients. These regressions appear to occur in the absence of massive CTL responses. To detect low-level responses, we resorted to antigenic stimulation of blood lymphocyte cultures in limiting dilution conditions, followed by tetramer analysis, cloning of the tetramer-positive cells, and T-cell receptor (TCR) sequence analysis of the CTL clones that showed strict specificity for the tumor antigen. A monoclonal CTL response against a MAGE-3 antigen was observed in a melanoma patient, who showed partial rejection of a large metastasis after treatment with a vaccine containing only the tumor-specific antigenic peptide. Tetramer analysis afterin vitrorestimulation indicated that about 1/40,000 postimmunization CD8+blood lymphocytes were directed against the antigen. The same TCR was present in all of the positive microcultures. TCR evaluation carried out directly on blood lymphocytes by PCR amplification led to a similar frequency estimate after immunization, whereas the TCR was not found among 2.5 × 106CD8+lymphocytes collected before immunization. Our results prove unambiguously that vaccines containing only a tumor-specific antigenic peptide can elicit a CTL response. Even though they provide no information about the effector mechanisms responsible for the observed reduction in tumor mass in this patient, they would suggest that low-level CTL responses can initiate tumor rejection.


  • From tumor antigens to immunotherapy

    by P. G. Coulie, T. Hanagiri, M. Takenoyama


  • Biological and clinical developments in melanoma vaccines

    by Marie Marchand, Vincent Brichard, Nicolas van Baren, Pierre G Coulie

    The identification of antigens recognised on human tumours by autologous T-lymphocytes has opened the way for vaccination strategies involving defined tumour antigens. These vaccinations are therapeutic, i.e. they involve patients with detectable disease. Tumour regressions have been observed in a minority of melanoma patients in Phase I/II trials. Some of these regressions have been complete and long lasting. Improving the efficacy of therapeutic vaccines will critically depend on their capacity to trigger a robust immune response, on the development of appropriate methods to monitor these antitumour immune responses to vaccination and on a better understanding of the mechanisms used by tumours to escape immune attack. Finally, the initiation of large randomised Phase III trials will determine the impact of these vaccines on melanoma treatment.